Therapy Area - Pharmaceutical Technology https://www.pharmaceutical-technology.com/sector/therapy-area/ The leading site for news and procurement in the pharmaceutical industry Thu, 22 Aug 2024 13:43:00 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.1 https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2022/01/cropped-Pharmaceutical-Technology-Favicon-150x150.png Therapy Area - Pharmaceutical Technology https://www.pharmaceutical-technology.com/sector/therapy-area/ 32 32 Lexicon to face FDA AdComm for Zynquista approval in diabetes and CKD https://www.pharmaceutical-technology.com/news/lexicon-to-face-fda-adcomm-for-zynquista-approval-in-diabetes-and-ckd/ Thu, 22 Aug 2024 13:42:44 +0000 https://www.pharmaceutical-technology.com/news/lexicon-to-face-fda-adcomm-for-zynquista-approval-in-diabetes-and-ckd/ Leo Pharma’s Timber bet falls flat following Phase III failure https://www.pharmaceutical-technology.com/news/leo-pharmas-timber-bet-falls-flat-following-phase-iii-failure/ Thu, 22 Aug 2024 11:31:44 +0000 https://www.pharmaceutical-technology.com/uncategorized/leo-pharmas-timber-bet-falls-flat-following-phase-iii-failure/ FDA declines to approve Regeneron’s linvoseltamab amid manufacturing issues https://www.pharmaceutical-technology.com/news/fda-declines-to-approve-regenerons-linvoseltamab-amid-manufacturing-issues/ Wed, 21 Aug 2024 16:09:52 +0000 https://www.pharmaceutical-technology.com/news/fda-declines-to-approve-regenerons-linvoseltamab-amid-manufacturing-issues/ Aadi axes 80% of staff after registrational Phase II trial fails https://www.pharmaceutical-technology.com/news/aadi-axes-80-of-staff-after-registrational-phase-ii-trial-fails/ Wed, 21 Aug 2024 14:40:14 +0000 https://www.pharmaceutical-technology.com/news/aadi-axes-80-of-staff-after-registrational-phase-ii-trial-fails/ Licensing agreements for innovator GLP1R drugs weigh in with over $6.2bn in 2024 https://www.pharmaceutical-technology.com/analyst-comment/licensing-agreements-for-innovator-glp1r-drugs-weigh-in-with-over-6-2bn-in-2024/ Wed, 21 Aug 2024 13:30:57 +0000 https://www.pharmaceutical-technology.com/analyst-comment/licensing-agreements-for-innovator-glp1r-drugs-weigh-in-with-over-6-2bn-in-2024/ How personalised medicine can revolutionise contraception https://www.pharmaceutical-technology.com/analyst-comment/how-personalised-medicine-revolutionise-contraception/ Wed, 21 Aug 2024 12:50:08 +0000 https://www.pharmaceutical-technology.com/analyst-comment/how-personalised-medicine-revolutionise-contraception/ NMPA approves AstraZeneca’s Fasenra for severe asthma https://www.pharmaceutical-technology.com/news/china-astrazeneca-fasenra-asthma/ Wed, 21 Aug 2024 10:06:03 +0000 https://www.pharmaceutical-technology.com/news/china-astrazeneca-fasenra-asthma/ Amgen’s Otezla launched for paediatric plaque psoriasis in US https://www.pharmaceutical-technology.com/news/amgens-otezla-plaque-psoriasis/ Wed, 21 Aug 2024 08:18:17 +0000 https://www.pharmaceutical-technology.com/news/amgens-otezla-plaque-psoriasis/ Organon and Lilly expand deal for migraine treatment to new markets https://www.pharmaceutical-technology.com/news/organon-lilly-migraine-treatment/ Wed, 21 Aug 2024 08:13:51 +0000 https://www.pharmaceutical-technology.com/news/organon-lilly-migraine-treatment/ Emergent joins mpox fight with 50,000 vaccine dose donation to Africa https://www.pharmaceutical-technology.com/news/emergent-joins-mpox-fight-with-50000-vaccine-dose-donation-to-africa/ Tue, 20 Aug 2024 15:33:02 +0000 https://www.pharmaceutical-technology.com/news/emergent-joins-mpox-fight-with-50000-vaccine-dose-donation-to-africa/